FibroGen fails again in DMD, continuing rotten run of phase 3 flops

FibroGen’s rotten run continues. The biotech reported its fourth phase 3 failure in as many months after the market closed Tuesday, flunking a second Duchenne muscular dystrophy (DMD) trial in quick succession to send it deeper into the mire.